Treatment of XXXX due to @entity2743 with @entity54327 .

@entity1 @entity2743 @entity54327 @entity1378 @entity3938
We describe the effect of administration of repeated doses of @entity54327 in a newborn @entity1 with @entity1378 due to transient @entity2743 . Pretreatment (day 3) serum T4 and @entity3938 concentrations were 49 micrograms/dl and 590 ng/dl, respectively. With 24 h after the first dose of ipodate, serum @entity3938 fell by 40%, and it subsequently ranged from 209-278 ng/dl throughout the 39-day ipodate treatment period. Serum T4 also decreased after ipodate administration to 69% and 41% of the pretreatment value after 72 h and 7 days of treatment, respectively; values thereafter during treatment ranged from 19-22 micrograms/dl. These plateau values are in the upper range of normal for the neonatal period. Rapid clinical improvement occurred as the hyperiodothyroninemia abated. Serum @entity3938 concentrations increased from 468-672 ng/dl to greater than 1400 ng/dl 24 h after each ipodate dose. Thyroid-stimulating immunoglobulin was present in maternal and cord sera, and the half-life of serum thyroid-stimulating immunoglobulin in the @entity1 was approximately 12 days. Antithyroglobulin and antimicrosomal antibodies were present in the @entity1 at 10 days of age, and the titers decreased progressively thereafter; the half-life for the antimicrosomal antibody titer was 3 weeks. The data suggest that @entity54327 can be useful for treatment of @entity1378 due to @entity2743 .
